公开(公告)号：US20170087127A1

公开(公告)日：2017-03-30

申请号：US15343859

申请日：2016-11-04

Applicant: Cadila Healthcare Limited

Inventor： Pankaj Patel ,  Rajendrakumar Hariprasad Jani

IPC: A61K31/40

CPC classification number: A61K31/40 ,  Y10S514/893

Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).

公开(公告)号：US20160166539A1

公开(公告)日：2016-06-16

申请号：US14782609

申请日：2013-06-25

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Pankaj PATEL ,  Rajendrakumar Hariprasad Jani

IPC: A61K31/40

CPC classification number: A61K31/40 ,  Y10S514/893

Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).

Abstract translation: 本发明提供了式（I）化合物或其药学上可接受的盐，其中“R”在本文中被描述。 此外，本发明涉及包含有效治疗量的式（I）化合物的组合物和使用该化合物治疗或预防障碍的方法，例如非酒精性脂肪肝疾病（NAFLD），包括脂肪肝（脂肪变性），非酒精性脂肪性肝炎（NASH） ）和肝硬化（肝脏晚期瘢痕形成）。

公开(公告)号：US09814697B2

公开(公告)日：2017-11-14

申请号：US15343859

申请日：2016-11-04

Applicant: Cadila Healthcare Limited

Inventor： Pankaj Patel ,  Rajendrakumar Hariprasad Jani

IPC: A61K31/40

CPC classification number: A61K31/40 ,  Y10S514/893

Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).

公开(公告)号：US20170088514A1

公开(公告)日：2017-03-30

申请号：US15345035

申请日：2016-11-07

Applicant: Cadila Healthcare Limited

Inventor： Dhiraj Gambhire ,  Rajendrakumar Hariprasad Jani ,  Bipin Pandey ,  Kaushik Sata ,  Himanshu Kothari ,  Pankaj Ramanbhai Patel

IPC: C07D207/33

CPC classification number: C07D207/333 ,  A61K9/2009 ,  A61K9/2013 ,  A61K31/40 ,  A61K45/06 ,  C07D207/33

Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

公开(公告)号：US20190100492A1

公开(公告)日：2019-04-04

申请号：US15992957

申请日：2018-05-30

Applicant: Cadila Healthcare Limited

Inventor： Dhiraj Gambhire ,  Rajendrakumar Hariprasad Jani ,  Bipin Pandey ,  Kaushik Sata ,  Himanshu Kothari ,  Pankaj Ramanbhai Patel

IPC: C07D207/333 ,  C07D207/33 ,  A61K45/06

Abstract: The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

公开(公告)号：US20180185330A1

公开(公告)日：2018-07-05

申请号：US15801738

申请日：2017-11-02

Applicant: Cadila Healthcare Limited

Inventor： Pankaj Patel ,  Rajendrakumar Hariprasad Jani

IPC: A61K31/40

CPC classification number: A61K31/40 ,  Y10S514/893

Abstract: The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein ‘R’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).